Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by H. Michael Shepard
Reactivating p53 mutants selectively in patients
Get full text access Log in, subscribe or purchase for full access. References 1. Bykov, V.J.N. ∙ Issaeva, N. ∙ Shilov, A. ... Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 2002; 8:282-288 2. Chen, S. ∙ Wu, J.L. ∙ Liang, Y. ... Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site Cancer Cell. 2021; 39:225-239.e8 3. Song, H. ∙ Wu, J. ∙ Tang, Y. ...
Trastuzumab: dreams, desperation and hope - Nature Reviews Cancer
The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a cancer therapy that attacks tumour cells, not normal cells, and Dennis Slamon’s drive to save the lives of people with breast cancer.
Biomarker-Driven Drug Discovery in Cancer-Trastuzumab Development: 2019 Lasker-DeBakey Clinical Medical Research Award
The 2019 Lasker-DeBakey Clinical Medical Research Award has been presented to H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich for the invention of trastuzumab, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer. The trastuzumab discovery program started with the urgent unmet need to create cancer drugs that were safe for patients, but deadly for tumors.
The Team that Just Wouldn’t Quit and a New Paradigm in Cancer Drug Discovery
Receiving the Lasker award for Clinical Medical Research is a staggering event. Perhaps equally staggering is the fact that as many as 2 million women worldwide have now been treated with Herceptin (trastuzumab), many of whom benefited from the treatment. This accomplishment is wonderfully rewarding for everyone who has been involved. There is a particular event that started us down this road.
2019 Lasker Awards
Celebrating the 2019 Lasker Awards: A Cell Collection Cell is pleased to celebrate the 2019 Lasker Awards with articles highlighting the winners’ groundbreaking contributions to science and society. In this year’s collection, which includes opening remarks from Joseph L.
Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
AbstractPurpose: The tumor microenvironment (TME) evolves to support tumor progression. One marker of more aggressive malignancy is hyaluronan (HA) accumulation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with H. Michael
Contact H. Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack